Virax Biolabs Group Limited Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for VRAX, updated each market day.
VRAX AI Sentiment
AI predicts Virax Biolabs Group Limited Ordinary Shares stock is likely to decrease over the next 10 market days.
Prediction date: July 17, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Exchange
Market Cap
$3,108,253
Cap Tier
Employees
26
Listed Since
July 21, 2022
Website
VRAX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VRAX Volatility
Virax Biolabs Group Limited Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
